Michal Tomasz Marzec
Michal Marzec graduated as MD from the Medical University of Warsaw in 2000 and took his PhD in 2011 from the University of Bialystok. He was a visiting scholar and later Research Associate at the Department of Pathology and Laboratory Medicine at the University of Pennsylvania, USA (2001-2010).
He subsequently moved to the Abramson Pediatric Research Centre, Children’s Hospital, Pennsylvania, where within his 5 year NIH K01 grant he investigated the role of endoplasmic reticulum chaperones and their human variants in the context of hormone production.
Dr. Marzec has published 36 scientific publications of which 34 are original papers in high impact peer-reviewed international journals including Diabetes, PlosOne, American Journal of Physiology, PNAS, Blood, Oncogene, Cancer Res, J Immunol and J Biol Chem, 4 as a senior author, 13 as 1st author. He has an H-index of 22; total citations: 2460; citations since 2016: 1150.
Dr. Marzec is a Member of Editorial board of journal Biology and a grant reviewer for Polish Ministry of Science and Higher Education and US-Israel Binational Science Foundation.
He is also a reviewer for the journals of Diabetes, Diabetologia, PlosOne, Blood, Cell Discovery, International Journal of Molecular Sciences, ACS Medicinal Chemistry Letters, Laboratory Investigation, Leukemia, Oncogene.
Primary fields of research
Over the years, Michal's research interest has shifted from understanding oncogenic pathways to providing answers to why and how organisms differ in their susceptibility to diseases. Recent massive sequencing of thousands of individuals made it possible to study the impact of human variations on pathological processes underlying multiple diseases. He joined prof. Argon’s laboratory, to work on the involvement of GRP94 in the maturation and secretion of IGF molecules. Subsequently, he described the first human variant of GRP94 and its role in the pathogenesis of Primary IGF Deficiency.
Currently he is applying his expertise into diabetes pathology where he recently identified GRP94 chaperone as a molecule indispensable for proper proinsulin handling. In addition he is exploring the possible link between population genetic variability of protein chaperones and the susceptibility to diabetes.